Immuno-Oncology 360° Community News’ Post

Dr. Roy Baynes of Eikon Therapeutics joined us to discuss his process of developing pembrolizumab, also known as Keytruda. Applying his experience as CMO and Head of Development at Merck, he explains what it takes to successfully develop an oncology therapeutic. Read the article here: https://lnkd.in/eCwvmyvV! #ClinicalTrials #DrugDevelopment #Keytruda

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics